Document:

Form of Indemnity Agreement

  
 Exhibit 10.9

 INDEMNITY AGREEMENT 
 THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of
                    , is made by and between DIADEXUS, INC., a Delaware corporation (the
“Company”), and                      (“Indemnitee”). 

RECITALS 
 A. The Company desires to attract and retain the services of highly qualified individuals as directors, officers, employees and agents. 

B. The Company’s bylaws (the “Bylaws”) require that the Company indemnify its directors, and
empowers the Company to indemnify its officers, employees and agents, as authorized by the Delaware General Corporation Law, as amended (the “Code”), under which the Company is organized and such Bylaws expressly provide that the
indemnification provided therein is not exclusive and contemplates that the Company may enter into separate agreements with its directors, officers and other persons to set forth specific indemnification provisions. 

C. Indemnitee does not regard the protection currently provided by applicable law, the Company’s governing
documents and available insurance as adequate under the present circumstances, and the Company has determined that Indemnitee and other directors, officers, employees and agents of the Company may not be willing to serve or continue to serve in such
capacities without additional protection. 
 D. The Company desires and has requested Indemnitee to serve
or continue to serve as a director, officer, employee or agent of the Company, as the case may be, and has proferred this Agreement to Indemnitee as an additional inducement to serve in such capacity. 

E. Indemnitee is willing to serve, or to continue to serve, as a director, officer, employee or agent of the
Company, as the case may be, if Indemnitee is furnished the indemnity provided for herein by the Company. 

AGREEMENT 
 NOW THEREFORE, in consideration of the mutual covenants and agreements set forth herein, the parties hereto, intending to be legally bound, hereby agree
as follows: 
 1. Definitions. 

(a) Agent. For purposes of this Agreement, the term “agent” of the Company means any person who:
(i) is or was a director, officer, employee or other fiduciary of the Company or a subsidiary of the Company; or (ii) is or was serving at the request or for the convenience of, or representing the interests of, the Company or a
subsidiary of the Company, as a director, officer, employee or other fiduciary of a foreign or domestic corporation, partnership, joint venture, trust or other enterprise. 

  
 (b)
Expenses. For purposes of this Agreement, the term “expenses” shall be broadly construed and shall include, without limitation, all direct and indirect costs of any type or nature whatsoever (including, without limitation, all
attorneys’, witness, or other professional fees and related disbursements, and other out-of-pocket costs of whatever nature), actually and reasonably incurred by Indemnitee in connection with the investigation, defense or appeal of a proceeding
or establishing or enforcing a right to indemnification under this Agreement, the Code or otherwise, and amounts paid in settlement by or on behalf of Indemnitee, but shall not include any judgments, fines or penalties actually levied against
Indemnitee for such individual’s violations of law. The term “expenses” shall also include reasonable compensation for time spent by Indemnitee for which he is not compensated by the Company or any subsidiary or third party
(i) for any period during which Indemnitee is not an agent, in the employment of, or providing services for compensation to, the Company or any subsidiary; and (ii) if the rate of compensation and estimated time involved is approved by the
directors of the Company who are not parties to any action with respect to which expenses are incurred, for Indemnitee while an agent of, employed by, or providing services for compensation to, the Company or any subsidiary. 

(c) Proceedings. For purposes of this Agreement, the term “proceeding” shall be broadly construed and
shall include, without limitation, any threatened, pending, or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding,
whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative or investigative nature, and whether formal or informal in any case, in which Indemnitee was, is or will be involved as a party or otherwise by
reason of: (i) the fact that Indemnitee is or was a director or officer of the Company; (ii) the fact that any action taken by Indemnitee or of any action on Indemnitee’s part while acting as director, officer, employee or agent of
the Company; or (iii) the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and
in any such case described above, whether or not serving in any such capacity at the time any liability or expense is incurred for which indemnification, reimbursement, or advancement of expenses may be provided under this Agreement. 

(d) Subsidiary. For purposes of this Agreement, the term “subsidiary” means any corporation or limited
liability company of which more than 50% of the outstanding voting securities or equity interests are owned, directly or indirectly, by the Company and one or more of its subsidiaries, and any other corporation, limited liability company,
partnership, joint venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary. 

(e) Independent Counsel. For purposes of this Agreement, the term “independent counsel” means a law
firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company or Indemnitee in
any matter material to either such party, or (ii) any other party to the proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “independent counsel” shall not include any person who,
under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. 

  
 2 

  
 2.
Agreement to Serve. Indemnitee will serve, or continue to serve, as a director, officer, employee or agent of the Company or any subsidiary, as the case may be, faithfully and to the best of his or her ability, at the will of such corporation
(or under separate agreement, if such agreement exists), in the capacity Indemnitee currently serves as an agent of such corporation, so long as Indemnitee is duly appointed or elected and qualified in accordance with the applicable provisions of
the bylaws or other applicable charter documents of such corporation, or until such time as Indemnitee tenders his or her resignation in writing; provided, however, that nothing contained in this Agreement is intended as an employment agreement
between Indemnitee and the Company or any of its subsidiaries or to create any right to continued employment of Indemnitee with the Company or any of its subsidiaries in any capacity. 

The Company acknowledges that it has entered into this Agreement and assumes the obligations imposed on it hereby, in
addition to and separate from its obligations to Indemnitee under the Bylaws, to induce Indemnitee to serve, or continue to serve, as a director, officer, employee or agent of the Company, and the Company acknowledges that Indemnitee is relying upon
this Agreement in serving as a director, officer, employee or agent of the Company. 
 3.
Indemnification. 
 (a) Indemnification in Third Party Proceedings. Subject to Section 10 below,
the Company shall indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, only to the extent that such amendment permits Indemnitee to broader indemnification rights than the Code
permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding, for any and all expenses, actually and reasonably incurred by Indemnitee in connection with the
investigation, defense, settlement or appeal of such proceeding. 
 (b) Indemnification in Derivative Actions
and Direct Actions by the Company. Subject to Section 10 below, the Company shall indemnify Indemnitee to the fullest extent permitted by the Code, as the same may be amended from time to time (but, only to the extent that such amendment
permits Indemnitee to broader indemnification rights than the Code permitted prior to adoption of such amendment), if Indemnitee is a party to or threatened to be made a party to or otherwise involved in any proceeding by or in the right of the
Company to procure a judgment in its favor, against any and all expenses actually and reasonably incurred by Indemnitee in connection with the investigation, defense, settlement, or appeal of such proceedings. 

4. Indemnification of Expenses of Successful Party. Notwithstanding any other provision of this Agreement, to the
extent that Indemnitee has been successful on the merits or otherwise in defense of any proceeding or in defense of any claim, issue or matter therein, including the dismissal of any action without prejudice, the Company shall indemnify Indemnitee
against all expenses actually and reasonably incurred in connection with the investigation, defense or appeal of such proceeding. 

  
 3 

  
 5.
Partial Indemnification. If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of any expenses actually and reasonably incurred by Indemnitee in the investigation, defense,
settlement or appeal of a proceeding, but is precluded by applicable law or the specific terms of this Agreement to indemnification for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion thereof to which
Indemnitee is entitled. 
 6. Advancement of Expenses. To the extent not prohibited by law, the Company
shall advance the expenses incurred by Indemnitee in connection with any proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall
include invoices received by Indemnitee in connection with such expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any
privilege accorded by applicable law shall not be included with the invoice) and upon request of the Company, an undertaking to repay the advancement of expenses if and to the extent that it is ultimately determined by a court of competent
jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. Advances shall be unsecured, interest free and without regard to Indemnitee’s ability to repay the expenses. Advances
shall include any and all expenses actually and reasonably incurred by Indemnitee pursuing an action to enforce Indemnitee’s right to indemnification under this Agreement, or otherwise and this right of advancement, including expenses incurred
preparing and forwarding statements to the Company to support the advances claimed. Indemnitee acknowledges that the execution and delivery of this Agreement shall constitute an undertaking providing that Indemnitee shall, to the fullest extent
required by law, repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. The right to
advances under this Section shall continue until final disposition of any proceeding, including any appeal therein. This Section 6 shall not apply to any claim made by Indemnitee for which indemnity is excluded pursuant to Section 10(b).

 7. Notice and Other Indemnification Procedures. 

(a) Notification of Proceeding. Indemnitee will notify the Company in writing promptly upon being served with any
summons, citation, subpoena, complaint, indictment, information or other document relating to any proceeding or matter which may be subject to indemnification or advancement of expenses covered hereunder. The failure of Indemnitee to so notify the
Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. 
 (b) Request for Indemnification and Indemnification Payments. Indemnitee shall notify the Company promptly in writing upon receiving notice of nay demand, judgment or other requirement for payment
that Indemnitee reasonably believes to the subject to indemnification under the terms of this Agreement, and shall request payment thereof by the Company. Indemnification payments requested by Indemnitee under Section 3 hereof shall be made by
the Company no later than sixty (60) days after receipt of the written request of Indemnitee. Claims for advancement of expenses shall be made under the provisions of Section 6 herein. 

  
 4 

  
 (c)
Application for Enforcement. In the event the Company fails to make timely payments as set forth in Sections 6 or 7(b) above, Indemnitee shall have the right to apply to any court of competent jurisdiction for the purpose of enforcing
Indemnitee’s right to indemnification or advancement of expenses pursuant to this Agreement. In such an enforcement hearing or proceeding, the burden of proof shall be on the Company to prove by that indemnification or advancement of expenses
to Indemnitee is not required under this Agreement or permitted by applicable law. Any determination by the Company (including its Board of Directors, stockholders or independent counsel) that Indemnitee is not entitled to indemnification hereunder,
shall not be a defense by the Company to the action nor create any presumption that Indemnitee is not entitled to indemnification or advancement of expenses hereunder. 

(d) Indemnification of Certain Expenses. The Company shall indemnify Indemnitee against all expenses incurred in
connection with any hearing or proceeding under this Section 7 unless the Company prevails in such hearing or proceeding on the merits in all material respects. 

8. Assumption of Defense. In the event the Company shall be requested by Indemnitee to pay the expenses of any
proceeding, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, or to participate to the extent permissible in such proceeding, with counsel reasonably acceptable to Indemnitee. Upon assumption of the defense by
the Company and the retention of such counsel by the Company, the Company shall not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that
Indemnitee shall have the right to employ separate counsel in such proceeding at Indemnitee’s sole cost and expense. Notwithstanding the foregoing, if Indemnitee’s counsel delivers a written notice to the Company stating that such counsel
has reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or the Company shall not, in fact, have employed counsel or otherwise actively pursued the defense of such
proceeding within a reasonable time, then in any such event the fees and expenses of Indemnitee’s counsel to defend such proceeding shall be subject to the indemnification and advancement of expenses provisions of this Agreement. 

9. Insurance. To the extent that the Company maintains an insurance policy or policies providing liability insurance
for directors, officers, employees, or agents of the Company or of any subsidiary (“D&O Insurance”), Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage
available for any such director, officer, employee or agent under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has D&O Insurance in effect, the Company shall give
prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf
of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. 

  
 5 

  
 10.
Exceptions. 
 (a) Certain Matters. Any provision herein to the contrary notwithstanding, the Company
shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee on account of any proceeding with respect to (i) remuneration paid to Indemnitee if it is determined by final judgment or other final adjudication that such
remuneration was in violation of law (and, in this respect, both the Company and Indemnitee have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is
against public policy and is, therefore, unenforceable and that claims for indemnification should be submitted to appropriate courts for adjudication, as indicated in Section 10(d) below); (ii) a final judgment rendered against Indemnitee
for an accounting, disgorgement or repayment of profits made from the purchase or sale by Indemnitee of securities of the Company against Indemnitee pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended,
or other provisions of any federal, state or local statute or rules and regulations thereunder; (iii) a final judgment or other final adjudication that Indemnitee’s conduct was in bad faith, knowingly fraudulent or deliberately dishonest
or constituted willful misconduct (but only to the extent of such specific determination); or (iv) on account of conduct that is established by a final judgment as constituting a breach of Indemnitee’s duty of loyalty to the Company or
resulting in any personal profit or advantage to which Indemnitee is not legally entitled. For purposes of the foregoing sentence, a final judgment or other adjudication may be reached in either the underlying proceeding or action in connection with
which indemnification is sought or a separate proceeding or action to establish rights and liabilities under this Agreement. 
 (b) Claims Initiated by Indemnitee. Any provision herein to the contrary notwithstanding, the Company shall not be obligated to indemnify or advance expenses to Indemnitee with respect to
proceedings or claims initiated or brought by Indemnitee against the Company or its directors, officers, employees or other agents and not by way of defense, except (i) with respect to proceedings brought to establish or enforce a right to
indemnification under this Agreement or under any other agreement, provision in the Bylaws or Certificate of Incorporation or applicable law, or (ii) with respect to any other proceeding initiated by Indemnitee that is either approved by the
Board of Directors or Indemnitee’s participation is required by applicable law. However, indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors determines it to be appropriate.

 (c) Unauthorized Settlements. Any provision herein to the contrary notwithstanding, the Company shall
not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee under this Agreement for any amounts paid in settlement of a proceeding effected without the Company’s written consent. Neither the Company nor Indemnitee shall
unreasonably withhold consent to any proposed settlement; provided, however, that the Company may in any event decline to consent to (or to otherwise admit or agree to any liability for indemnification hereunder in respect of) any proposed
settlement if the Company is also a party in such proceeding and determines in good faith that such settlement is not in the best interests of the Company and its stockholders. 

  
 6 

  
 (d)
Securities Act Liabilities. Any provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement to indemnify Indemnitee or otherwise act in violation of any undertaking appearing in
and required by the rules and regulations promulgated under the Securities Act of 1933, as amended (the “Act”), or in any registration statement filed with the SEC under the Act. Indemnitee acknowledges that paragraph (h) of
Item 512 of Regulation S-K currently generally requires the Company to undertake in connection with any registration statement filed under the Act to submit the issue of the enforceability of Indemnitee’s rights under this Agreement in
connection with any liability under the Act on public policy grounds to a court of appropriate jurisdiction and to be governed by any final adjudication of such issue. Indemnitee specifically agrees that any such undertaking shall supersede the
provisions of this Agreement and to be bound by any such undertaking. 
 11. Nonexclusivity and Survival of
Rights. The provisions for indemnification and advancement of expenses set forth in this Agreement shall not be deemed exclusive of any other rights which Indemnitee may at any time be entitled under any provision of applicable law, the
Company’s Certificate of Incorporation, Bylaws or other agreements, both as to action in Indemnitee’s official capacity and Indemnitee’s action as an agent of the Company, in any court in which a proceeding is brought, and
Indemnitee’s rights hereunder shall continue after Indemnitee has ceased acting as an agent of the Company and shall inure to the benefit of the heirs, executors, administrators and assigns of Indemnitee. The obligations and duties of the
Company to Indemnitee under this Agreement shall be binding on the Company and its successors and assigns until terminated in accordance with its terms. The Company shall require any successor (whether direct or indirect, by purchase, merger,
consolidation or otherwise) to all or substantially all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no
such succession had taken place. 
 No amendment, alteration or repeal of this Agreement or of any provision
hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her corporate status prior to such amendment, alteration or repeal. To the extent that a change in the
Code, whether by statute or judicial decision, permits greater indemnification or advancement of expenses than would be afforded currently under the Company’s Certificate of Incorporation, Bylaws and this Agreement, it is the intent of the
parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be
cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, by Indemnitee shall not prevent the
concurrent assertion or employment of any other right or remedy by Indemnitee. 
 12. Term. This
Agreement shall continue until and terminate upon the later of: (a) five (5) years after the date that Indemnitee shall have ceased to serve as a director or and/or officer, employee or agent of the Company; or (b) one (1) year
after the final termination of any proceeding, including any appeal then pending, in respect to which Indemnitee was granted rights of indemnification or advancement of expenses hereunder. 

  
 7 

  
 No
legal action shall be brought and no cause of action shall be asserted by or in the right of the Company against an Indemnitee or an Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives after the expiration of five
(5) years from the date of accrual of such cause of action, and any claim or cause of action of the Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five-year period; provided,
however, that if any shorter period of limitations is otherwise applicable to such cause of action, such shorter period shall govern. 
 13. Subrogation. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who, at the request and
expense of the Company, shall execute all papers required and shall do everything that may be reasonably necessary to secure such rights, including the execution of such documents necessary to enable the Company effectively to bring suit to enforce
such rights. 
 14. Interpretation of Agreement. It is understood that the parties hereto intend this
Agreement to be interpreted and enforced so as to provide indemnification to Indemnitee to the fullest extent now or hereafter permitted by law. 
 15. Severability. If any provision of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever, (a) the validity, legality and enforceability of the
remaining provisions of the Agreement (including without limitation, all portions of any paragraphs of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or
unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions of this Agreement (including, without limitation, all portions of any paragraph of this Agreement containing any such
provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable and to give
effect to Section 14 hereof. 
 16. Amendment and Waiver. No supplement, modification, amendment, or
cancellation of this Agreement shall be binding unless executed in writing by the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not
similar) nor shall such waiver constitute a continuing waiver. 
 17. Notice. Except as otherwise
provided herein, any notice or demand which, by the provisions hereof, is required or which may be given to or served upon the parties hereto shall be in writing and, if by telegram, telecopy or telex, shall be deemed to have been validly served,
given or delivered when sent, if by overnight delivery, courier or personal delivery, shall be deemed to have been validly served, given or delivered upon actual delivery and, if mailed, shall be deemed to have been validly served, given or
delivered three (3) business days after deposit in the United States mail, as registered or certified mail, with proper postage prepaid and addressed to the party or parties to be notified at the addresses set forth on the signature page of
this Agreement (or such other address(es) as a party may designate for itself by like notice). If to the Company, notices and demands shall be delivered to the attention of the Secretary of the Company. 

  
 8 

  
 18.
Governing Law. This Agreement shall be governed exclusively by and construed according to the laws of the State of California, as applied to contracts between California residents entered into and to be performed entirely within California.

 19. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for
all purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement. 

20. Headings. The headings of the sections of this Agreement are inserted for convenience only and shall not be
deemed to constitute part of this Agreement or to affect the construction hereof. 
 21. Entire
Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, understandings and negotiations, written and oral, between the parties with respect to
the subject matter of this Agreement; provided, however, that this Agreement is a supplement to and in furtherance of the Company’s Certificate of Incorporation, Bylaws, the Code and any other applicable law, and shall not be deemed a
substitute therefor, and does not diminish or abrogate any rights of Indemnitee thereunder. 

IN WITNESS WHEREOF, the parties hereto have entered
into this Agreement effective as of the date first above written. 
  

					
	 diaDexus, Inc.

		
	 By:
	 	  

		 	 Name:
	 	  

		 	 Title:
	 	  

	
	 INDEMNITEE

	
	  

	 Signature of Indemnitee

	
	 Print or Type Name of Indemnitee

  
 9SB/HGS Diagnostic License Agreement

  
 Exhibit 10.10

 SB/HGS DIAGNOSTIC LICENSE AGREEMENT 

This Agreement is effective as of this 24th day of July, 1997 between, on the one hand, SmithKline Beecham Corporation, a
corporation organized under the laws of the Commonwealth of Pennsylvania, having a place of business at One Franklin Plaza, Philadelphia, Pennsylvania 19101, U.S.A. (“SB corp”), SmithKline Beecham p.l.c., a corporation organized under the
laws of England and having a place of business at Great West Road, Brentford, Middlesex, U.K. (“SB p.l.c.”) (individually and collectively “SB”), and, on the other hand, Human Genome Sciences, Inc., 9410 Key West Avenue,
Rockville, Maryland 20850 (“HGS”). 
 WITNESSETH THAT: 

WHEREAS SB corp and HGS entered into the COLLABORATION AGREEMENT (defined below) relating to sequencing of expressed
genes and development of practical applications therefor; and 
 WHEREAS SB and HGS now wish to amend the
COLLABORATION AGREEMENT with respect to HUMAN DIAGNOSTIC PRODUCTS (defined below); 
 NOW, THEREFORE, in consideration of the
covenants and obligations expressed herein, and intending to be legally. bound, and otherwise to be bound by proper and reasonable conduct, the parties agree as follows: 

The parties now agree that the COLLABORATION AGREEMENT is superseded in accordance with Paragraph 23.01 of such agreement
and the AMENDED AND RESTATED LICENSE AGREEMENT is superseded, both only with respect to HUMAN DIAGNOSTIC PRODUCTS to read as follows: 
  

	1.	 DEFINITIONS 

  

	 	1.1.	 “AFFILIATE” shall mean any corporation, firm, partnership or other entity, whether de jure or de facto, which directly or
indirectly owns, is owned by or is under common ownership with a party to this Agreement to the extent of at least fifty percent (50%) of the equity (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in
a particular jurisdiction) having the power to vote on or direct the affairs of the entity and any person, firm, partnership, corporation or other entity actually controlled by, controlling or under common control with a party to this Agreement.

  

	 	1.2.	 “AMENDED AND RESTATED LICENSE AGREEMENT” shall mean the agreement between SB and HGS entered into May 31,1995.

  

	 	1.3.	 “ANTIBODY PRODUCT” shall mean an antibody (monoclonal or polyclonal) and fragments and constructs thereof which may be useful for the
treatment or prevention of a disease or disorder in humans. 

  

	 	1.4.	 “BIOINFORMATICS” shall mean computer software and know-how useful for the analysis, comparison, and curation of human nucleic acid
sequences; and information related to such sequences; and software for the 

	 	 
construction and maintenance of databases for the compilation of such sequences and their associated information; each developed from May 19, 1993 through the end of the INITIAL RESEARCH
TERM. BIOINFORMATICS shall include software for the prediction of the three-dimensional structure of proteins from primary sequence information but BIOINFORlVlA TICS shall not include software for rational drug design based on such three-dimensional
structure. To the extent BIOINFORMATICS includes software licensed from a THIRD PARTY such THIRD PARTY software is not included except to the extent that a party has the right to transfer to the other party such software and its use and the other
party agrees to pay any royalty owed to the THIRD PARTY for such software and its use. 

  

	 	1.5.	 “cDNA” shall mean complementary DNA prepared from human cells. 

 

	 	1.6.	 “CLINICAL STUDY” shall mean a study in humans of a product which study is intended for use in obtaining approval to sell the product in a
“Major Market.” However, in the case of a product for which no human clinical studies are required, then CLINICAL STUDY shall mean, instead, initiation of country-wide sales of a product in a “Major Market.” By “Major
Market” is meant the United States, Canada, Japan, Great Britain, France, Germany, or Italy. 

  

	 	1.7.	 “COLLABORATION AGREEMENT” shall mean the Collaboration Agreement entered into between SB and HGS effective as of May 19, 1993, as
amended as of immediately before the EFFECTIVE DATE. 

  

	 	1.8.	 “COLLABORATION PARTNER” shall mean those entities which are set forth in Appendix B of the JUNE 1996 SB/HGS LICENSE AGREEMENT, and any
entity added to such Appendix pursuant to that agreement by mutual written agreement between SB and HGS. 

  

	 	1.9.	 “COLLABORATION PARTNER AGREEMENT” shall mean an agreement among HGS and SB and a COLLABORATION PARTNER and designated in writing by SB and
HGS as a COLLABORATION PARTNER AGREEMENT, pursuant to the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	 	1.10.	 “COLLABORATION PARTNER PATENT” shall mean all patents and patent applications filed during the INITIAL RESEARCH TERM which are or become
owned by a COLLABORATION PARTNER or to which a COLLABORATION PARTNER otherwise has, now or in the future, the right to grant licenses, only to the extent HGS and SB have the rights to grant licenses thereto under a COLLABORATION PARTNER AGREEMENT.
Included within the defmition of COLLABORATION PARTNER PATENTS are all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, registrations, confirmations, re-examinations thereof and any provisional
applications and all SPCs. 

  
 2 

  

	 	1.11.	 “COLLABORATION PRODUCT” shall mean any product, process, substance, composition or service which (i) is based on the use of or is
derived by use of HGS TECHNOLOGY and/or SB TECHNOLOGY and/or (ii) is covered by a HGS PATENT and/or (iii) is covered by a SB PATENT; and/or (iv) is covered by a COLLABORATION PARTNER PATENT; and/or (v) is based on or is derived
by use of a TARGET and/or is a THERAPEUTIC PROTEIN and/or biological information on such TARGET or THERAPEUTIC PROTEIN all as to which SB and/or HGS receives rights from a COLLABORATION PARTNER under a COLLABORATION PARTNER AGREEMENT. An incidental
or immaterial use (or no use) of such technology or patents in (i)-(v) shall not cause a product, process, substance, composition or service to become a COLLABORATION PRODUCT. 

 

	 	1.12.	 “DIAGNOSTIC RESEARCH PLAN” shall mean a written plan for researching, developing and commercializing a HUMAN DIAGNOSTIC PRODUCT. An
example of such a plan is shown in Appendix A. RESEARCH PROGRAMS under the COLLABORATION AGREEMENT submitted prior to the EFFECTIVE DATE shall be deemed, to the extent that they cover HUMAN DIAGNOSTIC PRODUCTS, DIAGNOSTIC RESEARCH PLANS submitted by
SB under this Agreement in accordance with Section 4.1. 

  

	 	1.13.	 “DRUG PRODUCT” shall mean a product (including VACCINES, as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT), which is not a THERAPEUTIC
PROTEIN, GENE THERAPY VACCINE (as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT) or ANTIBODY PRODUCT, which may be useful for the treatment or prevention of a disease or disorder in a human. 

 

	 	1.14.	 “EFFECTIVE DATE” shall mean the date first written above. 

 

	 	1.15.	 “GENE” shall mean a eDNA or a human gene or a family of such human genes or any portion of such cDNA, gene or genes.

  

	 	1.16.	 “HGS” shall mean Human Genome Sciences, Inc. 

 

	 	1.17.	 “HGS HUMAN DIAGNOSTIC PRODUCT” shall mean a COLLABORATION PRODUCT that is a HUMAN DIAGNOSTIC PRODUCT to which HGS obtains rights in
accordance with Section 4 and as to which HGS retains rights under this Agreement. 

  

	 	1.18.	 “HGS PATENT(S)” shall mean all patents and patent applications to the extent they claim HGS TECHNOLOGY, which are or become owned by

  
 3 

	 	 
HGS or to which HGS otherwise has, now or in the future, the right to grant licenses. Included within the definition of HGS PATENTS are all continuations, continuations-in-part, divisions,
patents of addition, reissues, renewals, extensions, registrations, confirmations, reexaminations thereof and any provisional applications and all SPCs. 

 

	 	1.19.	 “HGS PRODUCT” shall mean (I) a COLLABORATION PRODUCT in the HGS FIELD; or (2) a COLLABORATION PRODUCT in the SB FIELD
(a) to which HGS obtains .rights in accordance with the JUNE 1996 SB/HGS LICENSE AGREEMENT; and/or (b) which is a THERAPEUTIC PROTEIN discovered or developed by or on behalf of HGS after the INITIAL RESEARCH TERM; and/or (c) which is
a DRUG PRODUCT or ANTIBODY PRODUCT discovered or developed by or on behalf of HGS at any time. 

  

	 	1.20.	 “HGS TECHNOLOGY” shall mean any and all data, substances, processes, materials, formulae, know-how and inventions with respect to GENES
and/or expression products thereof (including sequence and function) which are useful within the HGS FIELD, SB FIELD, and/or the field of HUMAN DIAGNOSTIC PRODUCTS, and which are developed by or on behalf of HGS during or prior to the INITIAL
RESEARCH TERM and which are owned by HGS or with respect to which HGS has a right to grant a license. In the event HGS in-licenses from a THIRD PARTY a DRUG PRODUCT, ANTIBODY PRODUCT, THERAPEUTIC PROTEIN or HUMAN DIAGNOSTIC PRODUCT in each case
discovered by a THIRD PARTY with no use of HGS TECHNOLOGY, such product and information generated by HGS directly related to the research and development of such product, shall not be HGS TECHNOLOGY. 

 

	 	1.21.	 “HGS SPECIAL TECHNOLOGY shall mean (1) all HGS TECHNOLOGY in existence prior to June 28, 1996 and required to be transferred under
the JUNE 1996 SB/HGS LICENSE AGREEMENT or transferred to SB under the COLLABORATION AGREEMENT or the JUNE 1996 SB/HGS LICENSE AGREEMENT and (2) all HGS TECHNOLOGY developed by or for HGS after June 28, 1996 and during the INITIAL RESEARCH
TERM required to be transferred under the JUNE 1996 SB/HGS LICENSE AGREEMENT or transferred to SB by HGS under the JUNE 1996 SB/HGS LICENSE AGREEMENT which is: (a) sequence data with respect to cDNA and expression products thereof and
BIOINFORMATICS relating thereto, (b) information on biological function of TARGETS and screens for such TARGETS, and/or (c) biological information on THERAPEUTIC PROTEINS for their use as TARGETS, and (3) HGS clones containing
sequences in (1) and 2(a). 

  

	 	1.22.	 “HUMAN DIAGNOSTIC PRODUCTS” shall mean any substance, process, composition or service intended to identify, analyze or detect one

  
 4 

	 	 
or more characteristics, genes, proteins, or any other molecule of, or in an individual human, including but not limited to, forensics, diagnosis, prognosis, or monitoring of a disease,
predisposition to a disease, or other abnormality or evaluation of health. HUMAN DIAGNOSTIC PRODUCTS shall also include such products intended for commercial sale for research in laboratory animals. It is expressly understood that a HUMAN DIAGNOSTIC
PRODUCT includes DIAGNOSTIC(S) as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	 	1.23.	 “INITIAL RESEARCH TERM” shall mean the term beginning May 19, 1993 and ending June 30, 2001. 

 

	 	1.24.	 “JUNE 1996 SB/HGS LICENSE AGREEMENT” shall mean the SB/HGS LICENSE AGREEMENT entered into between SB and HGS effective as of June 28,
1996. 

  

	 	1.25.	 “make, have made, use and sell” shall mean all exclusionary rights now or in the future conferred by a patent or equivalent of a patent
(e.g., a SPC), copyright, or trade secret law of each applicable respective jurisdiction of the world, including but not limited to the right to make, have made, use, offer to sell, sell, import, copy, display, and distribute.

  

	 	1.26.	 “NET SALES” shall mean gross receipts from sales of a SB HUMAN DIAGNOSTIC PRODUCT or a HGS HUMAN DIAGNOSTIC PRODUCT, as the case may be,
(on a product-by-product basis) by SB or HGS or, except as provided below, their respective AFFILIATES, licensees, distributors trading on SB’s or HGS’s account or joint ventures or other associated companies, less deductions for
(i) transportation, shipping and postage charges, including transportation, insurance, and customs duties to the extent separately invoiced; (ii) sales and excise taxes and duties paid or allowed by a selling party and any other
governmental charges imposed upon the production, importation, use or sale of such product; (iii) normal and customary trade, quantity and cash discounts allowed and rebates including but not limited to Medicaid and Medicaid-like rebates; and
(iv) allowances or credits to customers on account of rejection or return of such product or on account of retroactive price reductions affecting such product. Sales between or among a party to this Agreement and its respective AFFILIATES,
licensees, distributors trading on SB’s or HGS’s account, or joint ventures or other associated companies shall be included within NET SALES only if such purchaser is an end-user of the applicable HUMAN DIAGNOSTIC PRODUCT. Otherwise, NET
SALES shall only include the subsequent, final sales to THIRD PARTIES. 

  

	 	1.27.	 “PROTEIN RESEARCH PLAN” shall mean a written plan to research and develop a THERAPEUTIC PROTEIN, as such plan is defined in the JUNE 1996
SBIHGS LICENSE AGREEMENT. 

  
 5 

  

	 	1.28.	 “RESEARCH PLAN” shall have the same meaning as in the JUNE 1996 SB/HGS LICENSE AGREEMENT, except that it shall also include DIAGNOSTIC
RESEARCH PLANS. 

  

	 	1.29.	 “RESEARCH PROGRAM” shall have the meaning ascribed to it in the COLLABORATION AGREEMENT. 

 

	 	1.30.	 “RESEARCH TERM EXTENSIONS” shall mean extensions of the INITIAL RESEARCH TERM obtained pursuant to Paragraph 6.1.

  

	 	1.31.	 “SB” shall mean SmithKline Beecham Corporation and/or SmithKline Beecham, p.l.c., and any past (from May 19, 1993 through the
EFFECTIVE DATE), present or future AFFILIATE thereof, which AFFILIATE holds the relevant right and/or is or was or will be necessary or required to perform any obligations of SB under this Agreement and/or obligations of either of them are
subsequently assigned and/or delegated pursuant to Section 20 of this Agreement. 

  

	 	1.32.	 “SB FIELD” shall have the same meaning as in the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

 

	 	1.33.	 “SB HUMAN DIAGNOSTIC PRODUCT” shall mean a COLLABORATION PRODUCT that is a HUMAN DIAGNOSTIC PRODUCT to which SB obtains rights pursuant to
Section 4 and as to which SB retains rights under this Agreement. 

  

	 	1.34.	 “SB PATENT(s)” shall mean all patents and patent applications to the extent they claim SB TECHNOLOGY, which are or become owned by SB or
to which SB otherwise has, now or in the future, the right to grant licenses. Included within the definition of SB PATENTS are all continuations, continuations-in-part, divisions, patents of addition, reissues, renewals, extensions, registrations,
confirmations, re-examinations thereof and any provisional applications and all SPCs. SB PATENTS shall include TAKEDA PATENTS, as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT, to the extent such patents and patent applications claim SB
TECHNOLOGY. 

  

	 	1.35.	 “SB DIAGNOSTIC PATENT(s)” shall mean SB PATENT(s), only to the extent such patents have claims that cover a HUMAN DIAGNOSTIC PRODUCT.

  

	 	1.36.	 “SB TECHNOLOGY” shall mean any and all data, substances, processes, materials, formulae, know-how, inventions and information useful
within the HGS FIELD, SB FIELD, and/or the field of HUMAN DIAGNOSTIC PRODUCTS, which are based on the use of or derived by use of HGS SPECIAL TECHNOLOGY and are developed by or on behalf of SB during the INITIAL RESEARCH TERM, or RESEARCH TERM
EXTENSIONS 

  
 6 

	 	 
or under a RESEARCH PLAN submitted by SB pursuant to this Agreement prior to the later of four (4) years after the INITIAL RESEARCH TERM or four (4) years after RESEARCH TERM
EXTENSIONS. SB TECHNOLOGY shall not include technologies, reagents or materials made by SB merely because of an incidental or immaterial use (or no use of) of HGS SPECIAL TECHNOLOGY in the development of such technologies, reagents or materials or
merely because of an incidental or immaterial use of (or no use of) such technologies, reagents or materials in a RESEARCH PLAN. SB TECHNOLOGY shall include TAKEDA TECHNOLOGY, as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT, to the extent that
such TAKEDA TECHNOLOGY is based on the use of or derived by use of (a) HGS SPECIAL TECHNOLOGY, or (b) SB TECHNOLOGY as defined in the preceding two sentences of this Paragraph. 

 

	 	1.37.	 “SPC” shall mean a right based upon a patent to exclude others from making, using or selling a product, process, substance, composition or
service, such as a Supplementary Protection Certificate. 

  

	 	1.38.	 “SPECIAL SB TECHNOLOGY” shall mean (I) all SB TECHNOLOGY developed by or on behalf of SB in existence prior to June 28, 1996
required to be transferred under the JUNE 1996 SB/HGS LICENSE AGREEMENT or transferred to HGS by SB under the COLLABORATION AGREEMENT or the JUNE 1996 SB/HGS LICENSE AGREEMENT, (2) all SB TECHNOLOGY developed by or on behalf of SB after
June 28, 1996 which SB is required to transfer or transfers to HGS under the JUNE 1996 SB/HGS LICENSE AGREEMENT and/or (3) SB TECHNOLOGY otherwise lawfully obtained by HGS. With respect to information contained in a DIAGNOSTIC RESEARCH
PLAN submitted by SB pursuant to this Agreement, SPECIAL SB TECHNOLOGY shall not include items of the type identified in Sections 1, 2, or 3 of the outline attached as Appendix A. 

 

	 	1.39.	 “TARGET” shall mean a GENE or expression product thereof (e.g., receptors, enzymes or ion channels) which could be used for screening or
other drug discovery purpose to identify compounds or antibodies with a biochemical or pharmacological effect. 

  

	 	1.40.	 “TERRITORY” shall mean all the countries and territories in the world. 

 

	 	1.41.	 “THERAPEUTIC PROTEIN” shall mean a polypeptide derived from a GENE (not including an ANTIBODY PRODUCT) which may be useful for the
treatment or prevention of a disease or disorder in humans. 

  

	 	1.42.	 “THIRD PARTY(IES)” shall mean any party other than a party to this Agreement or an AFFILIATE of SB, or HGS. 

  
 7 

  

	2.	 GRANTS 

  

	 	2.1.	 RESEARCH AND DEVELOPMENT 

  

	 	2.1.1.	 HGS hereby grants to SB a non-exclusive, world-wide license under HGS SPECIAL TECHNOLOGY, claims of HGS PATENTS that cover HGS SPECIAL TECHNOLOGY
and COLLABORATION PARTNER PATENTS to perform research and development of HUMAN DIAGNOSTIC PRODUCTS during the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS pursuant to this Agreement, provided however that HGS will not have a license to make,
have made, use and sell a HUMAN DIAGNOSTIC PRODUCT based on HGS diagnostic research except as described herein. 

  

	 	2.1.2.	 HGS hereby grants to SB a non-exclusive, world-wide, license under HGS SPECIAL TECHNOLOGY, claims of HGS PATENTS that cover HGS SPECIAL TECHNOLOGY
and COLLABORATION PARTNER PATENTS to perform research and development of HUMAN DIAGNOSTIC PRODUCTS after the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS pursuant to a DIAGNOSTIC RESEARCH PLAN submitted by SB pursuant to this Agreement.

  

	 	2.1.3.	 SB hereby grants to HGS a non-exclusive, world-wide, license under SB DIAGNOSTIC PATENTS to perform research and development of HUMAN DIAGNOSTIC
PRODUCTS during the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS, but not to the extent that such SB DIAGNOSTIC PATENT covers any SB HUMAN DIAGNOSTIC PRODUCT and/or any HUMAN DIAGNOSTIC PRODUCT which is the subject of a DIAGNOSTIC RESEARCH
PLAN filed by SB during the INITIAL RESEARCH TERM. 

  

	 	2.1.4.	 SB hereby grants to HGS a non-exclusive, world-wide, license under SB DIAGNOSTIC PATENTS to perform research and development of HUMAN DIAGNOSTIC
PRODUCTS after the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS pursuant to a DIAGNOSTIC RESEARCH PLAN submitted by HGS pursuant to this Agreement, but not to the extent that such SB DIAGNOSTIC PATENT covers any SB HUMAN DIAGNOSTIC PRODUCT
and/or any HUMAN DIAGNOSTIC PRODUCT which is the subject of a DIAGNOSTIC RESEARCH PLAN filed by SB during the INITIAL RESEARCH TERM. 

  

	 	2.1.5.	 HGS hereby grants to SB a non-exclusive, world-wide, license under HGS SPECIAL TECHNOLOGY, HGS PATENTS AND COLLABORATION PARTNER PATENTS to perform
research 

  
 8 

	 	 
and development in the HGS FIELD (as that term is defined in the June 1996 SB/HGS LICENSE AGREEMENT) only in furtherance of research and development of HUMAN DIAGNOSTIC PRODUCTS (i) during
the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS, and (ii) after the INITIAL RESEARCH TERM under a RESEARCH PLAN submitted by SB pursuant to this Agreement. For the avoidance of doubt, no license is granted (other than to perform research
and development pursuant to this Section 2. 1. 5) to SB hereunder to make, have made, use and sell COLLABORATION PRODUCTS in the HGS FIELD. 

  

	 	2.2.	 SB HUMAN DIAGNOSTIC PRODUCTS 

  

	 	2.2.1.	 HGS hereby grants to SB an exclusive, sublicenseable world-wide license under HGS SPECIAL TECHNOLOGY, claims of HGS PATENTS that cover HGS SPECIAL
TECHNOLOGY, and COLLABORATION PARTNER PATENTS to make, have made, use and sell in the TERRITORY, each SB HUMAN DIAGNOSTIC PRODUCT, as to which SB obtains rights under Section 4 during the INITIAL RESEARCH TERM. 

 

	 	2.2.2.	 HGS hereby grants to SB a non-exclusive, sublicenseable worldwide license under HGS SPECIAL TECHNOLOGY, claims of HGS PATENTS that cover HGS SPECIAL
TECHNOLOGY, and COLLABORATION PARTNER PATENTS to make, have made, use and sell in the TERRITORY, each SB HUMAN DIAGNOSTIC PRODUCT, as to which SB obtains rights under Section 4 during RESEARCH TERM EXTENSIONS. 

 

	 	2.2.3.	 SB shall have the right to license SB HUMAN DIAGNOSTIC PRODUCTS at any time. 

 

	 	2.2.4.	 Except for agreements permitted by Paragraph 7.2 or the JUNE 1996 SB/HGS LICENSE AGREEMENT, the rights granted to SB by HGS under this Agreement and
SB’s rights to SB TECHNOLOGY and SB PATENTS are licenseable and/or transferable by SB to a THIRD PARTY only with respect to a SB HUMAN DIAGNOSTIC PRODUCT, and only pursuant to an Agreement by which SB grants a license to a THIRD PARTY for a SB
HUMAN DIAGNOSTIC PRODUCT as permitted under this Paragraph 2.2.3 and in which the THIRD PARTY agrees to covenants and obligations with respect to the use of such SB HUMAN DIAGNOSTIC PRODUCT, and any HGS TECHNOLOGY, HGS PATENTS, SB PATENTS and SB
TECHNOLOGY to be licensed to such THIRD PARTY which are essentially identical to the covenants and obligations of SB under this Agreement. 

  
 9 

  

	 	2.3.	 HGS HUMAN DIAGNOSTIC PRODUCTS 

  

	 	2.3.1.	 SB hereby grants to HGS a non-exclusive, sublicenseable worldwide license under SB DIAGNOSTIC PATENTS to make, have made, use and sell in the
TERRITORY, each HGS HUMAN DIAGNOSTIC PRODUCT as to which HGS obtains rights under Section 4 during the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS, but not to the extent that such SB DIAGNOSTIC PATENT covers any SB HUMAN DIAGNOSTIC
PRODUCT and/or any HUMAN DIAGNOSTIC PRODUCT which is the subject of a DIAGNOSTIC RESEARCH PLAN filed by SB during the INITIAL RESEARCH TERM. 

  

	 	2.3.2.	 Except for agreements permitted by Paragraph 7.2, the rights to SB DIAGNOSTIC PATENTS granted to HGS by SB under this Agreement are licenseable
and/or transferable by HGS to a THIRD PARTY only with respect to a HGS HUMAN DIAGNOSTIC PRODUCT, and only pursuant to an Agreement by which HGS grants a license to a THIRD PARTY to a HGS HUMAN DIAGNOSTIC PRODUCT as permitted under this Agreement and
in which the THIRD PARTY agrees to covenants and obligations which limit the use of SB DIAGNOSTIC PATENTS which are essentially identical to the covenants and obligations of HGS under this Agreement. 

 

	 	2.3.3.	 Except for (i) licenses granted by HGS to SB under this Agreement; and (ii) licenses granted to THIRD PARTIES with respect to HGS HUMAN
DIAGNOSTIC PRODUCTS as permitted by Paragraph 2.3.2, during the INITIAL RESEARCH TERM, HGS shall not grant any rights or license to HUMAN DIAGNOSTIC PRODUCTS that are COLLABORATION PRODUCTS. In addition, during the INITIAL RESEARCH TERM, HGS shall
not grant to any THIRD PARTY diagnostic research rights to access the database or other diagnostic research and/or development rights other than those associated with the licensing of a specific HGS HUMAN DIAGNOSTIC PRODUCT as provided herein.

  

	 	2.3.4.	 Notwithstanding anything else to the contrary, SPECIAL SB TECHNOLOGY developed after June 28, 1996 and claims of SB PATENTS developed after
June 28, 1996, and RESEARCH PROGRAMS submitted under the COLLABORATION AGREEMENT shall not be disclosed by HGS to a THIRD PARTY until such patents and technology have, prior to such disclosure, become generally available to the public other
than through a breach of this Agreement. 

  
 10 

  

	 	2.4.	 All the grants in this Section 2 are subject to all the terms and conditions of the Agreement. 

 

	 	2.5.	 Except as expressly provided herein, SB retains all rights to SB DIAGNOSTIC PATENTS. 

 

	3.	 PAYMENTS AND ROYALTIES 

  

	 	3.1.	 Payments to HGS 

  

	 	3.1.1.	 SB shall pay a royalty of 2.5% (two and a half percent) of NET SALES of each SB HUMAN DIAGNOSTIC PRODUCT sold by SB or SB licensees.

  

	 	3.1.2.	 Royalty obligations on SB HUMAN DIAGNOSTIC PRODUCTS sold by SB or SB licensees under this Agreement shall terminate on a country-by-country and
product-by-product basis on the later of (i) ten (10) years after first country-wide launch of each product in each country or (ii) expiration of the COLLABORATION PARTNER PATENT, HGS PATENT or SB DIAGNOSTIC PATENT which covers the
making, using or selling of such product in such country. 

  

	 	3.2.	 Payments to SB 

  

	 	3.2.1.	 If a HGS HUMAN DIAGNOSTIC PRODUCT is sublicensed to a THIRD PARTY and such HGS HUMAN DIAGNOSTIC PRODUCT is covered by a claim of a SB DIAGNOSTIC
PATENT, then HGS shall pay a royalty of 2.5% (two and a half percent) of NET SALES of each such HGS HUMAN DIAGNOSTIC PRODUCT sold by such HGS licensee. Subject to Section 3.3, no royalty is owed on sales by HGS. 

 

	 	3.2.2.	 Royalty obligations on HGS HUMAN DIAGNOSTIC PRODUCTS sold by HGS licensees under this Agreement shall terminate on a country-by-country and
product-by-product basis on the later of (i) ten (10) years after first country-wide launch of each product in each country or (ii) expiration of the SB DIAGNOSTIC PATENT which covers the making, using or selling of such product in
such country. 

  

	 	3.3.	 ROYALTIES TO THIRD PARTIES 

  

	 	3.3.1.	 Any royalties owed to a THIRD PARTY, including a COLLABORATION PARTNER or TAKEDA, by HGS or SB, on the NET SALES of a SB HUMAN DIAGNOSTIC PRODUCT
shall be the sole responsibility of SB. 

  

	 	3.3.2.	 Any royalties owed to a THIRD PARTY, including a COLLABORATION PARTNER or TAKEDA, by HGS or SB, on the NET SALES of a HGS HUMAN DIAGNOSTIC PRODUCT
shall be the sole responsibility of HGS. 

  
 11 

  

	 	3.4.	 Except as provided in Sections 3.1, 3.2, or 3.3, no other payments or obligations, including but not limited to copromotion payments, milestones,
and licensing fees, shall be owed by either SB or HGS to the other for an SB DIAGNOSTIC PRODUCT or an HGS DIAGNOSTIC PRODUCT, as the case may be, under this Agreement or any other agreement between S B and HGS existing as of the EFFECTIVE DATE of
this Agreement. 

  

	4.	 DIAGNOSTIC RESEARCH PLANS 

  

	 	4.1.	 SB shall obtain rights in accordance with Section 2 of this Agreement to a HUMAN DIAGNOSTIC PRODUCT, provided that SB is the first among the
parties to this Agreement to submit a DIAGNOSTIC RESEARCH PLAN for the specific HUMAN DIAGNOSTIC PRODUCT during the INITIAL RESEARCH TERM or any RESEARCH TERM EXTENSIONS. If SB submits a DIAGNOSTIC RESEARCH PLAN for a specific HUMAN DIAGNOSTIC
PRODUCT that contains greater than twenty (20) analytes (gene, probe thereto, protein or other gene product) representing greater than . twenty (20) different GENES, each of which is HGS SPECIAL TECHNOLOGY, the DIAGNOSTIC RESEARCH PLAN
shall contain an experimental indication that at least 50% of the analytes to be contained in the HUMAN DIAGNOSTIC PRODUCT are potentially useful for the diagnosis of a specific disease, condition, prognostic determination, treatment outcome or
other indication of human health status. 

  

	 	4.2.	 Subject to the provisions of Sections 4. 1 and 4.3, HGS shall obtain rights in accordance with Section 2 of this Agreement to a HUMAN
DIAGNOSTIC PRODUCT, provided that HGS is the first among the parties to this Agreement to submit a DIAGNOSTIC RESEARCH PLAN for the specific HUMAN DIAGNOSTIC PRODUCT during the INITIAL RESEARCH TERM or any RESEARCH TERM EXTENSIONS.

  

	 	4.3.	 During the INITIAL RESEARCH TERM, HGS may only submit DIAGNOSTIC RESEARCH PLANS for HUMAN DIAGNOSTIC PRODUCTS in accordance with either of the
following conditions: 

  

	 	4.3.1.	 HGS may submit up to thirty-eight (38) DIAGNOSTIC RESEARCH PLANS for HUMAN DIAGNOSTIC PRODUCTS, one such plan in connection with each PROTEIN
RESEARCH PLAN submitted by HGS pursuant to the JUNE 1996 SB/HGS LICENSE AGREEMENT. The DIAGNOSTIC RESEARCH PLAN shall cover only the same GENE as the PROTEIN RESEARCH PLAN and/or expression product of such GENE and/or antibody against such
expression product. 

  

	 	4.3.2.	 HGS may submit a DIAGNOSTIC RESEARCH PLAN for a HUMAN DIAGNOSTIC PRODUCT which corresponds to a HGS PRODUCT, other than a THERAPEUTIC PROTEIN, at
the time 

  
 12 

	 	 
HGS or its licensee initiates a CLINICAL STUDY of such HGS PRODUCT (i.e., a DRUG PRODUCT or an ANTIBODY PRODUCT). If HGS submits a DIAGNOSTIC RESEARCH PLAN for a specific HUMAN DIAGNOSTIC PRODUCT
that contains greater than twenty (20) analytes (gene, probe thereto, protein or other gene product) representing greater than twenty (20) different GENES, each of which is HGS SPECIAL TECHNOLOGY, the DIAGNOSTIC RESEARCH PLAN shall contain
an experimental indication that at least 50% of the analytes to be contained in the HUMAN DIAGNOSTIC PRODUCT are potentially useful for the diagnosis of a specific disease, condition, prognostic determination, treatment outcome or other indication
of human health status. 

  

	 	4.4.	 ALL DIAGNOSTIC RESEARCH PLANS submitted by either party shall be submitted to the RC established under the JUNE 1996 SB/HGS LICENSE AGREEMENT.

  

	 	4.5.	 In the event that SB obtains rights to a SB HUMAN DIAGNOSTIC PRODUCT pursuant to Section 4. 1 and such diagnostic is directed to the same GENE
as a PROTEIN RESEARCH PLAN submitted by HGS pursuant to the JUNE 1996 SB/HGS LICENSE AGREEMENT, SB shall make such SB HUMAN DIAGNOSTIC PRODUCT available to HGS or its therapeutic licensee on standard commercial terms when such product becomes
available as a commercial product. 

  

	 	4.6.	 In the event that the research, development or commercialization of the THERAPEUTIC PROTEIN or HGS PRODUCT in connection with which a DIAGNOSTIC
RESEARCH PLAN has been submitted by HGS pursuant to Section 4. 3. 1 or 4. 3. 2 is terminated by HGS, all HGS rights under HGS PATENTS and know-how to the HGS HUMAN DIAGNOSTIC PRODUCT (which HGS HUMAN DIAGNOSTIC PRODUCT was contained in the
DIAGNOSTIC RESEARCH PLAN submitted by HGS in conjunction with said THERAPEUTIC PRODUCT or HGS PRODUCT) shall be assigned to SB. 

  

	5.	 PRODUCT DEVELOPMENT 

  

	 	5.1.	 SB shall have full control and authority over development, registration and commercialization of SB HUMAN DIAGNOSTIC PRODUCT. HGS shall have full
control and authority over development, registration and commercialization of HGS HUMAN DIAGNOSTIC PRODUCT. 

  

	 	5.2.	 Each party may delegate such responsibilities in whole or in part to its licensees. 

 

	 	5.3.	 Each party shall keep the other informed of progress of its efforts to develop and commercialize SB HUMAN DIAGNOSTIC PRODUCT or HGS

  
 13 

	 	 
HUMAN DIAGNOSTIC PRODUCT. Each party shall keep the other party informed of its, and its licensees progress to develop and commercialize SB HUMAN DIAGNOSTIC PRODUCTS or HGS HUMAN DIAGNOSTIC
PRODUCTS as the case may be. 

  

	 	5.4.	 SB shall use its diligent efforts to develop, market, promote and sell SB HUMAN DIAGNOSTIC PRODUCT as to which SB obtains rights under
Section 4 equivalent to those efforts it uses with respect to products of similar value and status, subject to SB’s right to terminate such efforts and surrender such rights in and to such product. 

 

	 	5.5.	 HGS shall use its diligent efforts to develop, promote and sell HGS HUMAN DIAGNOSTIC PRODUCT as to which HGS obtains rights to under Section 4
equivalent to those efforts it uses with respect to products of similar value and status, subject to HGS’s right to terminate such efforts and surrender such exclusive rights in and to such product. 

 

	 	5.6.	 Within sixty (60) days after the end of each calendar year, SB and HGS shall provide to each other in writing annual reports with respect to
work performed by or for it under DIAGNOSTIC RESEARCH PLANS which shall consist of updates to DIAGNOSTIC RESEARCH PLANS substantially in the form of the APPENDIX A. 

 

	 	5.7.	 SB and HGS shall not use any information or data in RESEARCH PLANS submitted by the other, other than information which is HGS SPECIAL TECHNOLOGY
AND SPECIAL SB TECHNOLOGY as specified in Sections 1,2 and 3 of a RESEARCH PLAN. 

  

	6.	 RESEARCH TERM EXTENSIONS 

  

	 	6.1.	 The INITIAL RESEARCH TERM may be extended by SB as RESEARCH TERM EXTENSIONS for up to five (5) additional years on a year-by-year basis by
written notice to HGS at least sixty (60) days prior to the end of the INITIAL RESEARCH TERM or any yearly extension thereof, provided (I) such written notice is accompanied by a payment of Two Million U.S. Dollars ($2,000,000) for each
additional year; and (2) SB has extended the INITIAL RESEARCH TERM of the JUNE 1996 SB/HGS LICENSE AGREEMENT for the same period of time. 

  

	7.	 EXCHANGE OF INFORMATION AND CONFIDENTIALITY 

 

	 	7.1.	 During the term of this Agreement and thereafter, irrespective of any termination earlier than the expiration of the term of this Agreement, HGS and
SB shall not use or reveal or disclose to THIRD PARTIES any information or materials received from the other party, without first obtaining the written consent of such other party, except as permitted hereunder. This confidentiality and non-use
obligation shall not apply to disclosures to or uses by TAKEDA pursuant to the SB/TAKEDA AGREEMENT or disclosures to or uses by COLLABORATION 

  
 14 

	 	 
PARTNERS pursuant to COLLABORATION PARTNER AGREEMENTS. Unless otherwise restricted by this Agreement, the confidentiality and non-use provisions of this Paragraph shall not apply to such
information which 

  

	 	a)	 was known to the receiving party or generally known to the public prior to its disclosure hereunder; 

 

	 	b)	 subsequently becomes known to the public by some means other than a breach of this Agreement; 

 

	 	c)	 is subsequently disclosed to the receiving party by a THIRD PARTY having a lawful right to make such disclosure; 

 

	 	d)	 is required by law or bona fide legal process to be disclosed, provided that the party required to make the disclosure takes all reasonable steps to
restrict and maintain confidentiality of such disclosure and provides reasonable notice to the party providing the information and/or materials; 

  

	 	e)	 is approved for release by the parties, or 

  

	 	f)	 is independently developed by employees or agents of either party or their respective parent corporation or their AFFILIATES and/or subsidiaries
without any knowledge of the information and/or materials provided by the other party. 

  

	 	7.2.	      

  

	 	7.2.1.	 Nothing in Paragraph 7. 1 shall be construed as preventing either party from disclosing any information to an AFFILIATE or to a licensee,
distributor or joint venture or other associated company of either party for the purpose of developing or commercializing SB HUMAN DIAGNOSTIC PRODUCT, or HGS HUMAN DIAGNOSTIC PRODUCT as permitted by this Agreement, provided such AFFILIATE, licensee,
distributor or joint venture or other associated company has undertaken a similar obligation of confidentiality and non-use with respect to the confidential information. 

 

	 	7.2.2.	 In the event that SB intends to transfer or disclose HGS SPECIAL TECHNOLOGY or SB TECHNOLOGY to a THIRD PARTY collaborator that is a not-for-profit
entity (and/or an investigator working for a not-for-profit entity) no such transfer or disclosure shall take place until such THIRD PARTY enters into an agreement with SB by which SB is granted a license to all inventions and patent rights based
thereon which result from the use of such technology. To the extent any such invention would be HGS TECHNOLOGY or SB TECHNOLOGY if invented or discovered by SB and/or HGS, then such invention shall be HGS TECHNOLOGY or SB TECHNOLOGY as the case may
be subject to the terms and conditions of this Agreement. HGS agrees that SB may enter into agreements pursuant to this Paragraph using an Agreement substantially in the form of MTAs used by SB and/or HGS under the COLLABORATION AGREEMENT.

  
 15 

  

	 	7.2.3.	 Either party may disclose HGS TECHNOLOGY and SB TECHNOLOGY to THIRD PARTY contractors or collaborators to facilitate or carry out research
activities under this Agreement provided that such THIRD PARTIES enter into an agreement with such party which contains confidentiality provisions substantially the same as those set forth herein and which provides that all rights in inventions and
which result from the use of such technology by the THIRD PARTY shall be owned by HGS or SB or exclusively licensed to HGS or SB as the case may be with a right to grant licenses. To the extent any such invention or discovery would be HGS TECHNOLOGY
or SB TECHNOLOGY if invented or discovered by SB and/or HGS, then such invention or discovery shall be HGS TECHNOLOGY or SB TECHNOLOGY as the case may be subject to the terms and conditions of this Agreement. 

 

	 	7.3.	 All confidential information disclosed by one party to the other shall remain the intellectual property of the disclosing party. In the event that a
court or other legal or administrative tribunal, directly or through an appointed master, trustee or receiver, assumes partial or complete control over the assets of a party to this Agreement based on the insolvency or bankruptcy of such party, the
bankrupt or insolvent party shall promptly notify the court or other tribunal (i) that confidential information received from the other party under this Agreement remains the property of the other party and (ii) of the confidentiality
obligations under this Agreement. In addition, the bankrupt or insolvent party shall, to the extent permitted by law, take all steps necessary or desirable to maintain the confidentiality of the other party’s confidential information and to
insure that the court, other tribunal or appointee maintains such information in confidence in accordance with the terms of this Agreement. 

  

	 	7.4.	 No public announcement concerning (i) the existence of or terms of this Agreement (ii) research and/or discoveries made by a party and,
(iii) exercise of a party of rights granted under this Agreement shall be made, either directly or indirectly, by the other party to this Agreement without prior written notice to the other party and, except as may be legally required, or as
may be required for a public offering of securities, or as may be required for recording purposes, without first obtaining the approval of the other party and agreement upon the nature and text of such announcement. The party desiring to make any
such public announcement shall inform the other party of the proposed announcement or disclosure in reasonably sufficient time prior to public release, and shall provide the other party with a written copy thereof, in order to allow such other party
to comment upon such announcement or disclosure. This Paragraph shall not apply to any information in a public announcement which is information essentially identical to that contained in a previous public announcement agreed to pursuant to this
Paragraph. 

  
 16 

  

	 	7.5.	 For the avoidance of doubt, nothing in this Agreement shall be construed as preventing or in any way inhibiting either party from complying with
statutory and regulatory requirements governing the development, manufacture, use and sale or other distribution of products in any manner which it reasonably deems appropriate, including, for example, by disclosing to regulatory authorities
confidential or other information received from a party or THIRD PARTIES. The parties shall take reasonable measures to assure that no unauthorized use or disclosure is made by others to whom access to such information is granted. Any materials
provided by one party to the other under this Agreement shall be subject to the confidentiality and non-use provisions set out in this Section. All such materials shall be used in compliance with all applicable laws and regulations. SB and HGS each
certifies that it is regularly engaged in conducting tests in vitro or in animals used only for laboratory research purposes, that all materials which SB or HGS receive under this Agreement will actually be used for these purposes only, and that no
animal used for such tests will be used for any food purposes or kept as a domestic pet or livestock. 

  

	 	7.6.	 SB and HGS agree to comply with any applicable law or regulation of the United States or any country governing the export or reexport of products
(including test equipment), software, and technical data (and the product of such data). 

  

	 	7.7.	 All rights and licensing granted under or pursuant to this Agreement by HGS to SB are, and shall irrevocably be deemed to be, “intellectual
property” as defined in Section 101(56) of the Bankruptcy Code. In the event of the commencement of a case by or against either party under any Chapter of the Bankruptcy Code, this Agreement shall be deemed an executory contract and all
rights and obligations hereunder shall be determined in accordance with Section 365(n) thereof. Unless a party rejects this Agreement and the other party decides not to retain its rights hereunder, the other party shall be entitled to a
complete duplicate of (or complete access to, as appropriate) all intellectual property and all embodiments of such intellectual property held by the party and the party shall not interfere with the rights of the other party, which are expressly
granted hereunder, to such intellectual property and all embodiments of such intellectual property from another entity. Further, this Agreement shall be deemed, upon presentation to another entity, to be the same as an express instruction by the
party to such other entity to provide such intellectual property and all embodiments of such intellectual property directly to the other party. Without limiting the foregoing provisions in this Paragraph, the other party shall be entitled to all
post-bankruptcy-petition improvements, updates, or developments of intellectual property created 

  
 17 

	 	 
hereunder. If such intellectual property is not fully developed as of the commencement of any bankruptcy case, the other party shall have the right to complete development of the property.

  

	 	7.8.	 Nothing in this Agreement shall be construed as requiring HGS to disclose HGS SPECIAL TECHNOLOGY to SB or SB to disclose SB SPECIAL TECHNOLOGY to
HGS other than as already required under Section 12.1 of the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	8.	 PATENT PROSECUTION AND LITIGATION 

  

	 	8.1.	 Each party shall have and retain sole and exclusive title to all inventions, discoveries, designs, works of authorship and other know-how which are
made, conceived, reduced to practice or generated only by its employees, agents, or other persons acting under its authority. Each party shall own an equal undivided interest in all such inventions, discoveries, designs, works of authorship and
other know-how made, conceived, reduced to practice or generated jointly by employees, agents, or other persons acting under the authority of both parties. In the event of jointly owned inventions, HGS shall have the first right to file, prosecute
and maintain patents and applications directed thereto under the terms and conditions of Paragraph 8.2. If a joint owner does not desire to file, prosecute or maintain a patent or patent application to a joint inventions, such owner shall assign its
ownership interest therein to the other. All patents and patent applications to joint inventions which are HGS SPECIAL TECHNOLOGY and SPECIAL SB TECHNOLOGY shall be both SB PATENTS and HGS PATENTS, subject to the terms and conditions of this
Agreement; otherwise, any joint owner shall be free to dispose of its interest therein without accounting to the other joint owner. 

  

	 	8.2.	 HGS shall have the right within its sole discretion and at its expense to prepare, file, prosecute and maintain HGS PATENTS. With respect to HGS
PATENTS as to which SB retains a license hereunder, subject to Paragraph 8. 9, HGS shall keep SB informed with respect to the filing and prosecution thereof. In the event that SB desires that HGS obtain and maintain patent protection in any country
with respect to HGS SPECIAL TECHNOLOGY as to which SB retains a license hereunder, HGS shall do so at the cost and expense of SB. 

  

	 	8.3.	 SB shall have the right within its sole discretion and at its expense to prepare, file, prosecute and maintain SB PATENTS. With respect to SB
PATENTS as to which HGS retains a license hereunder, subject to Paragraph 8. 10, SB shall keep HGS informed with respect to the filing and prosecution thereof. In the event that HGS desires that SB obtain and maintain patent protection in any
country with respect to SPECIAL SB TECHNOLOGY as to which HGS retains a license hereunder, SB shall do so at the cost and expense of HGS. 

  
 18 

  

	 	8.4.	 Each party, on behalf of itself and its directors, employees, officers, shareholders, agents, successors and assigns hereby waives any and all
actions and causes of action, claims and demands whatsoever, in law or equity of any kind it or they may have against the other party, its officers, directors. employees, shareholders, agents, successors and assigns, which may arise in any way,
except as a result of gross negligence, recklessness, or willful misconduct, in performance of patent activities under this Section. 

  

	 	8.5.	 In the event that HGS or SB becomes aware of actual or threatened infringement of a SB PATENT or HGS PATENT anywhere in the TERRITORY. that party
shall promptly notify the other party in writing. The owner of the SB PATENT or HGS PATENT shall have the first right but not the obligation to bring, at its own expense, an infringement action against any THIRD PARTY and to use the other
party’s name in connection therewith. If the owner of the patent does not commence a particular infringement action within thirty (30) days, the other party, after notifying the owner in writing, shall be entitled to bring such
infringement action at its own expense to the extent that such party is licensed thereunder and in its own name and/or in the name of the owning party. The foregoing notwithstanding, in the event that an alleged infringer certifies pursuant to 21
USC 355(b)(2)(A)(vii)(IV) or (j)(2)(A)(iv) against an issued HGS PATENT or SB PATENT covering a HUMAN DIAGNOSTIC PRODUCT, the party receiving notice of such certification shall immediately notify the other party of such certification, and if
fourteen (14) days prior to expiration of the forty five (45) day period set forth in 21 USC 355(c)(3)(C) or (j)(4)(B)(iii), the owner of the HGS PATENT or SB PATENT fails to commence an infringement action, the party receiving notice, in
its sole discretion, at its own expense and to the extent that it is licensed under the HGS PATENT or SB PATENT, shall be entitled to bring such infringement action in its own name and/or in the name of the owning party. The party conducting such
action shall have full control over its conduct, including settlement thereof provided such settlement shall not be made without the prior written consent of the other party if it would adversely affect the patent rights of the other party. In any
event, HGS and SB shall assist one another and cooperate in any such litigation at the other’s request without expense to the requesting party. 

  

	 	8.6.	 HGS and SB shall recover their respective actual out-of-pocket expenses, or equitable proportions thereof, associated with any litigation or
settlement thereof from any recovery made by any party. Any excess amount shall be shared between SB and HGS in an amount proportional to their respective losses and expenses. 

 

	 	8.7.	 The parties shall keep one another informed of the status of and of their respective activities regarding any such litigation or settlement thereof.

  
 19 

  

	 	8.8.	 The owner of a SB PATENT or HGS PATENT shall have the first right to seek extensions of the terms of the patent and to seek to obtain SPCs. A party
who is developing, selling or planning to sell a product covered by a patent shall have the second right. Each party shall assist the other in the obtaining of such extensions or SPCs including by authorizing the other party to act as its agent.

  

	 	8.9.	 The disclosure obligations of Paragraph 8. 2 shall only apply to HGS PATENTS which include HGS SPECIAL TECHNOLOGY which HGS has disclosed to SB
pursuant to the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	 	8.10.	 The disclosure obligations of Paragraph 8. 3 shall only apply to SB PATENTS which claim SPECIAL SB TECHNOLOGY which SB has disclosed to HGS pursuant
to the JUNE 1996 SB HGS LICENSE AGREEMENT. 

  

	9.	 TRADEMARKS AND NON-PROPRIETARY NAMES 

 

	 	9.1.	 SB, at its expense, shall be responsible for the selection, registration and maintenance of all trademarks which it employs in connection with SB
HUMAN DIAGNOSTIC PRODUCT and shall own and control such trademarks. Nothing in this Agreement shall be construed as a grant of rights, by license or otherwise, to HGS to use such trademarks for any purpose other than as provided in this Agreement.

  

	 	9.2.	 SB, at its expense, shall be responsible for the selection and registration of non-proprietary names employed by SB for SB HUMAN DIAGNOSTIC PRODUCT.

  

	 	9.3.	 HGS, at its expense, shall be responsible for the selection, registration and maintenance of all trademarks which it employs in connection with HGS
HUMAN DIAGNOSTIC PRODUCT and shall own and control such trademarks. Nothing in this Agreement shall be construed as a grant of rights, by license or otherwise, to SB to use such trademarks for any purpose other than as provided in this Agreement.

  

	 	9.4.	 HGS, at its expense, shall be responsible for the selection and registration of non-proprietary names employed by HGS for HGS HUMAN DIAGNOSTIC
PRODUCT. 

  

	10.	 STATEMENTS AND REMITTANCES 

  

	 	10.1.	 Each party, as the case may be, shall keep and require its licensees to keep complete and accurate records of all NET SALES of HGS HUMAN DIAGNOSTIC
PRODUCT and SB HUMAN DIAGNOSTIC PRODUCT, subject to royalties under the licenses granted herein. Each party shall have the right, at its expense, through a certified public accountant or like person reasonably acceptable to the other party, to
examine such records during 

  
 20 

	 	 
regular business hours during the life of this Agreement and for six (6) months after its termination; provided, however, that such examination shall not take place more often than once a
year and provided further that such accountant shall report only as to the accuracy of the royalty statements and payments, including the magnitude and source of any discrepancy. Neither party nor their licensees shall be required to maintain such
records for more than three (3) years. 

  

	 	10.2.	 Within sixty (60) days after the close of each calendar quarter, each party shall deliver to the other a true accounting of all SB HUMAN
DIAGNOSTIC PRODUCT, or HGS HUMAN DIAGNOSTIC PRODUCT sold by it and its licensees and distributors during such quarter for which royalties are payable and shall at the same time pay all royalties due. Such accounting shall show sales on a
country-by-country and product-byproduct basis. 

  

	 	10.3.	 Any tax paid or required to be withheld on account of the licensing party based on royalties payable under this Agreement shall be deducted from the
amount of royalties otherwise due. Taxes paid or withheld from monies due SB by its licensees shall be deducted proportionately from the amount of monies otherwise due HGS. Each party shall secure and send to the other proof of any such taxes
withheld and paid. 

  

	 	10.4.	 All royalties due under this Agreement shall be payable in U.S. dollars. If governmental regulations prevent remittances from a foreign country with
respect to sales made in that country, the obligation to pay royalties on sales in that country shall be suspended until such remittances are possible. Each party shall have the right, upon giving written notice to the other, to receive payment in
that country in local currency. 

  

	 	10.5.	 Monetary conversions from the currency of a foreign country, in which a product is sold, into United States currency shall be made at the official
exchange rate in force in that country for financial transactions on the last business day of the calendar quarter or half year for which the royalties are being paid. If there is no such official exchange rate, the conversion shall be made at the
rate for such remittances on that date as certified by Citibank, N.A., New York, New York, U.S.A. 

  

	11.	 TERM AND TERMINATION 

  

	 	11.1.	 This Agreement shall come into effect as of the EFFECTIVE DATE and shall remain in full force and effect unless earlier terminated as provided in
this Section 11. 

  

	 	11.2.	 In the event HGS fails to make a payment to SB under this Agreement with respect to a HGS HUMAN DIAGNOSTIC PRODUCT when due, or fails to meet its
obligations under Section 5 with respect to a HGS HUMAN DIAGNOSTIC PRODUCT, in addition to any other remedy which it may 

  
 21 

	 	 
have, SB may notify HGS in writing that all of HGS’s rights with respect to such HGS HUMAN DIAGNOSTIC PRODUCT shall terminate as of sixty (60) days after such written notice and
HGS’s rights with respect thereto shall terminate unless such payment is made or such failure is cured, prior to the expiration of such sixty (60) day period. 

 

	 	11.3.	 In the event SB fails to make a payment to HGS under this Agreement with respect to a SB HUMAN DIAGNOSTIC PRODUCT when due, or fails to meet its
obligations under Section 5 with respect to a SB HUMAN DIAGNOSTIC PRODUCT, in addition to any other remedy which it may have, HGS may notify SB in writing that all of SB’s rights with respect to such SB HUMAN DIAGNOSTIC PRODUCT shall
terminate as of sixty (60) days after such written notice and SB’s rights with respect thereto shall terminate unless such payment is made or such failure is cured, prior to the expiration of such sixty (60) day period.

  

	 	11.4.	 Either party may terminate this Agreement if, at any time, the other party shall file in any court or agency pursuant to any statute or regulation
of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the party or of its assets, or if the other party proposes a written agreement of
composition or extension of its debts, or if the other party shall be served with an involuntary petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed within sixty (60) days after the filing thereof,
or if the other party shall propose or be a party to any dissolution or liquidation, or if the other party shall make an assignment for the benefit of creditors. 

 

	 	11.5.	 Notwithstanding the bankruptcy of HGS or SB, or the impairment of performance by HGS or SB of its obligations under this Agreement as a result of
bankruptcy or insolvency of HGS or SB, the other party shall be entitled to retain the licenses granted herein, subject to rights of a party to terminate this Agreement for reasons other than bankruptcy or insolvency as expressly provided in this
Agreement. 

  

	 	11.6.	 Neither party shall have the right to terminate this Agreement except under Paragraph 11. 4, provided however that nothing in this Agreement shall
limit any remedies for breach which may be available pursuant to a judgment of a court, in law or equity, including termination of this Agreement or of any or all rights hereunder. 

 

	12.	 RIGHTS AND DUTIES UPON TERMINATION 

  

	 	12.1.	 Upon termination of this Agreement in its entirety or with respect to any SB HUMAN DIAGNOSTIC PRODUCT or HGS HUMAN DIAGNOSTIC PRODUCT or to any
country, each party shall notify the other of the amount of such product it and its licensees and distributors then have on hand, the sale of which would, but for the termination, be subject to

  
 22 

	 	 
royalty, and such party and its licensees and distributors shall thereupon be permitted to sell that amount of the product provided that the party shall pay the royalty thereon at the time herein
provided for. 

  

	 	12.2.	 Termination of this Agreement shall terminate all outstanding obligations and liabilities between the parties arising from this Agreement except
those described in Paragraphs 2. 2. 4, 2.3.2, 2.3.4, 7.1, 7.3, 7.5, and 8.1 and Sections 10, 12, 14, 16, and 23, as well as any provision not specified in this Paragraph which is clearly meant to survive termination of this Agreement.

  

	 	12.3.	 Termination of the Agreement in accordance with the provisions hereof shall not limit remedies which may be otherwise available in law or equity.

  

	13.	 WARRANTIES AND REPRESENTATIONS 

Nothing in this Agreement shall be construed as a warranty that SB PATENTS, COLLABORATION PARTNER PATENTS or HGS
PATENTS are valid or enforceable or that their exercise does not infringe any patent rights of THIRD PARTIES. A holding of invalidity or unenforceability of any such patent, from which no further appeal is or can be taken, shall not affect
any obligation already accrued hereunder, but shall only eliminate royalties otherwise due under such patent from the date such holding becomes final. 
  

	 	13.1.	 Each party warrants and represents that it has the right to enter into this Agreement and to perform in accordance therewith.

  

	 	13.2.	 Except as otherwise expressly set forth herein neither party makes any representations or extends any warranties of any kind, either express or
implied, including, but /lot limited to, warranties of merchantability or fitness for a particular purpose. 

  

	 	13.3.	 Each party guarantees that its respective AFFILIATES will perform all obligations under this Agreement as if such AFFILIATES were signatories of
this Agreement. 

  

	14.	 INDEMNIFICATION 

  

	 	14.1.	 SB shall defend, indemnify and hold harmless HGS, AFFILIATES of HGS, licensors of HGS and their respective directors, officers, shareholders, agents
and employees, from and against any and all liability, loss, damages and expenses (including attorneys’ fees) as the result of claims, demands, costs or judgments which may be made or instituted against any of them arising out of the
manufacture, possession, distribution, use, testing, sale or other disposition by or through SB or any THIRD PARTY granted rights by SB under this Agreement of any SB HUMAN DIAGNOSTIC PRODUCT. SB’s obligation to defend, indemnify and hold
harmless shall include claims, demands, costs or judgments, whether for 

  
 23 

	 	 
money damages or equitable relief by reason of alleged personal injury (including death) to any person or alleged property damage, provided, however, the indemnity shall not extend to any claims
against an indemnified party which result from the gross negligence or willful misconduct of such indemnified party. SB shall have the exclusive right to control the defense of any action which is to be indemnified in whole by SB hereunder,
including the right to select counsel acceptable to HGS to defend HGS and to settle any claim, provided that, without the written consent of HGS (which shall not be unreasonably withheld or delayed), SB shall not agree to settle any claim against
HGS to the extent such claim has a material adverse effect on HGS. The provisions of this Paragraph shall survive and remain in full force and effect after any termination, expiration or cancellation of this Agreement and obligation hereunder shall
apply whether or not such claims are rightfully brought. SB shall require each licensee to agree to indemnify HGS in a manner consistent with this Paragraph. 

 

	 	14.2.	 HGS shall defend, indemnify and hold harmless SB, AFFILIATES of SB, licensors of SB and their respective directors, officers, shareholders, agents
and employees, from and against any and all liability, loss, damages and expenses (including attorneys’ fees) as the result of claims, demands, costs or judgments which may be made or instituted against any of them arising out of the
manufacture, possession, distribution, use, testing, sale or other disposition by or through HGS or its AFFILIATES or any THIRD PARTY granted rights by HGS under this Agreement of any HGS HUMAN DIAGNOSTIC PRODUCT. HGS’s obligation to defend,
indemnify and hold harmless shall include claims, demands, costs or judgments, whether for money damages or equitable relief by reason of alleged personal injury (including death) to any person or alleged property damage, provided, however, the
indemnity shall not extend to any claims against an indemnified party which result from the gross negligence or willful misconduct of such indemnified party. HGS shall have the exclusive right to control the defense of any action which is to be
indemnified in whole by HGS hereunder, including the right to select counsel acceptable to SB to defend SB and to settle any claim, provided that, without the written consent of SB (which shall not be unreasonably withheld or delayed), HGS shall not
agree to settle any claim against SB to the extent such claim has a material adverse effect on SB. The provisions of this Paragraph shall survive and remain in full force and effect after any termination, expiration or cancellation of this Agreement
and HGS obligation hereunder shall apply whether or not such claims are rightfully brought. HGS shall require each licensee to agree to indemnify SB in a manner consistent with this Paragraph. 

 

	 	14.3.	 A person or entity that intends to claim indemnification under this Section 14 (the “Indemnitee”) shall promptly notify the other party
(the “Indemnitor”) of any loss, claim, damage, liability or action in respect of which the Indemnitee intends to claim such indemnification, and the 

  
 24 

	 	 
Indemnitor, after it determines that indemnification is required of it, shall assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an Indemnitee
shall have the right to retain its own counsel, with the fees and expenses to be paid by the Indemnitor if Indemnitor does not assume the defense; or, if representation of such Indemnitee by the counsel retained by the Indemnitor would be
inappropriate due to actual or potential differing interests between such Indemnitee and any other party represented by such counsel in such proceedings. The indemnity agreement in this Section 14 shall not apply to amounts paid in settlement
of any loss, claim, damage, liability or action is such settlement is effected without the consent of the Indemnitor, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnitor within a reasonable time after
the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve such Indemnitor of any liability to the Indemnitee under this Section 14, but the omission so to deliver notice to the Indemnitor will not
relieve it of any liability that it may have to any Indemnitee otherwise than under this Section 14. The Indemnitee under this Section 14 its employees and agents, shall cooperate fully with the Indemnitor and its legal representatives in
the investigations of any action, claim or liability covered by this indemnification. In the event that each party claims indemnity from the other and one party is finally held liable to indemnify the other, the Indemnitor shall additionally be
liable to pay the reasonable legal costs and attorneys’ fees incurred by the Indemnitee in establishing its claim for indemnity. 

  

	15.	 FORCE MAJEURE 

  

	 	15.1.	 If the performance of any party of this Agreement by either party, or of any obligation under this Agreement, is prevented, restricted, interfered
with or delayed by reason of any clause beyond the reasonable control of the party liable to perform, unless conclusive evidence to the contrary is provided, the party so affected shall, upon giving written notice to the other party, be excused from
such performance to the extent of such prevention, restriction, interference or delay, provided that the affected party shall use its reasonable best efforts to avoid or remove such causes of non-performance and shall continue performance with the
utmost dispatch whenever such causes are removed. When such circumstances arise, the parties shall discuss what, if any, modification of the terms of this Agreement may be required in order to arrive at an equitable solution.

  

	16.	 GOVERNING LAW 

  

	 	16.1.	 This Agreement shall be deemed to have been made in the Commonwealth of Pennsylvania and its form, execution, validity, construction and effect
shall be determined in accordance with the laws of the Commonwealth of Pennsylvania, U.S.A. 

  
 25 

  

	17.	 SEPARABILITY 

  

	 	17.1.	 In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining portions hereof shall remain in full force and
effect. 

  

	 	17.2.	 If any of the terms or provisions of this Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall
be deemed inoperative to the extent that they may conflict therewith and shall be deemed to be modified to conform with such statute or rule of law. 

  

	 	17.3.	 In the event that the terms and conditions of this Agreement are materially altered as a result of Paragraphs 17. I or 17. 2, the parties will
renegotiate in good faith the terms and conditions of this Agreement to resolve any inequities. 

  

	18.	 ENTIRE AGREEMENT 

  

	 	18.1.	 This Agreement, the JUNE 1996 SB/HGS LICENSE AGREEMENT, and the COLLABORATION PARTNER AGREEMENTS entered into as of the date written above,
constitutes the entire agreement between the parties relating to the subject matter hereof and supersedes all previous writings and understandings relating to such subject matter. No terms or provisions of this Agreement shall be varied or modified
by any prior or subsequent statement, conduct or act of either of the parties, except that the parties may amend this Agreement by written instruments specifically referring to and executed in the same manner as this Agreement.

  

	 	18.2.	 The headings and titles to the Sections and Paragraphs of this Agreement are inserted for convenience only and shall not be deemed a part hereof or
affect the construction or interpretation of any provision hereof. 

  

	19.	 NOTICES 

  

	 	19.1.	 Any notice required or permitted under this Agreement shall be sent by air mail, postage pre-paid, courier or fax to the following addresses of the
parties or such other addresses as may be notified to the parties as provided herein: 

  

			
	 HGS:
	  	 HUMAN GENOME SCIENCES, INC.
 Key West Avenue
 Rockville, Maryland 20850

Attention: Chief Executive Officer
 fax: 301-309-0092

		
	 copy to:
	  	 HGS: HUMAN GENOME SCIENCES, INC.
 Key West Avenue
 Rockville, Maryland 20850

Attention: General Counsel
 fax: 301-309-8439

  
 26 

			
		
	 SB:
	  	 SMITHKLINE BEECHAM CORPORATION
 Swedeland Road
 King of Prussia, Pennsylvania 19103

Attention: Director,
 Alliances & Technologies Group
 SmithKline Beecham Pharmaceuticals

fax: 610-270-6663

		
	 copy to:
	  	 SMITHKLINE BEECHAM CORPORATION
 Swedeland Road
 P.O. Box 1539

King of Prussia, Pennsylvania 19406
 Attention: Corporate Intellectual Property
 fax:
610-270-4026

  

	 	19.2.	 Any notice required or permitted to be given concerning this Agreement shall be effective upon receipt by the party to whom it is addressed.

  

	20.	 ASSIGNMENT 

  

	 	20.1.	 This Agreement and the licenses herein granted shall be binding upon and inure to the benefit of the successors in interest of the respective
parties. Neither this Agreement nor any interest hereunder shall be assignable by either party without the written consent of the other provided. however, that SB or HGS may assign this Agreement or any of its rights or obligations hereunder
to any AFFILIATE or to any THIRD PARTY with which it may merge or consolidate, or to which it may transfer all or substantially all of its assets to which this Agreement relates, without obtaining the consent of the other party, provided the
assigning party remains liable under this Agreement and that the THIRD PARTY assignee or surviving entity assumes in writing all of its obligations under this Agreement. 

 

	21.	 RECORDING 

  

	 	21.1.	 SB and HGS shall have the right, at any time, to record, register, or otherwise notify this Agreement in appropriate governmental or regulatory
offices anywhere in the TERRITORY, and the other party shall provide reasonable assistance to the notifying party in effecting such recording, registering or notifying. 

 

	22.	 DISPUTE RESOLUTION 

  

	 	22.1.	 Senior management of SB and HGS shall endeavor to resolve all disputes under this Agreement. 

 

	 	22.2.	 If senior management does not timely resolve any such dispute. then either party may submit such to binding arbitration pursuant to the SB/HGS
arbitration agreement dated 19 August, 1993 as may be amended from time to time. 

  
 27 

  

	23.	 COVENANTS 

  

	 	23.1.	      

  

	 	23.1.1.	 SB agrees not to use SB TECHNOLOGY except 

  

	 	23.1.1.1.	 during the INITIAL RESEARCH TERM and RESEARCH TERM EXTENSIONS to perform research and development of HUMAN DIAGNOSTIC PRODUCTS and after the INITIAL
RESEARCH TERM and RESEARCH TERM EXTENSIONS to perform research and development of a SB HUMAN DIAGNOSTIC PRODUCT pursuant to a DIAGNOSTIC RESEARCH PLAN submitted by or on behalf of SB pursuant to this Agreement, 

 

	 	23.1.1.2.	 in the HGS FIELD (as defined in the JUNE 1996 SB/HGS LICENSE AGREEMENT) only (i) in furtherance of research and development of HUMAN DIAGNOSTIC
PRODUCTS during the INITIAL RESEARCH TERM AND RESEARCH TERM EXTENSIONS, and (ii) after the INITIAL RESEARCH TERM AND RESEARCH TERM EXTENSIONS only in furtherance of research and development of SB HUMAN DIAGNOSTIC PRODUCTS pursuant to a
DIAGNOSTIC RESEARCH PLAN submitted by or on behalf of SB pursuant to this Agreement, 

  

	 	23.1.1.3.	 to make, have made, use, and sell SB HUMAN DIAGNOSTIC PRODUCT (other than SB HUMAN DIAGNOSTIC PRODUCTS to which SB’s rights have been
terminated pursuant to Paragraph 11. 3), 

  

	 	23.1.1.4.	 to grant licenses that SB is otherwise permitted to grant pursuant to this Agreement, and 

 

	 	23.1.1.5.	 as otherwise permitted in the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

 

	 	23.1.2.	 During and after the INITIAL RESEARCH TERM, SB agrees not to use HGS SPECIAL TECHNOLOGY except as licensed and permitted pursuant to this Agreement
or the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	 	23.1.3.	 Notwithstanding the preceding, SB shall have the right to use SB TECHNOLOGY that is solely based on or derived from published information and/or
information which otherwise becomes lawfully known to SB independently of this Agreement, unless: (i) the information is claimed in a published HGS PATENT or SB PATENT and there is no THIRD PARTY patent application or patent with an earlier
priority date which discloses the information or (ii) the SB TECHNOLOGY results from a DIAGNOSTIC RESEARCH PLAN undertaken by SB. 

  
 28 

  

	 	23.2.	 HGS shall not use SPECIAL SB TECHNOLOGY except as licensed or permitted under this Agreement. Notwithstanding the preceding, HGS shall have the
right to use SPECIAL SB TECHNOLOGY independently of this Agreement if such SPECIAL SB TECHNOLOGY is solely based on or derived from published information and/or information which otherwise becomes lawfully known to HGS independently of this
Agreement, unless: the information is claimed in a published HGS PATENT or SB PATENT and there is no THIRD PARTY patent application or patent with an earlier priority date which discloses the information. 

 

	 	23.3.	 Notwithstanding anything else to the contrary, the following uses of SB TECHNOLOGY and/or HGS SPECIAL TECHNOLOGY shall not be a breach of this
Agreement by SB: 

  

	 	23.3.1.	 use of unpatented HGS TECHNOLOGY outside a RESEARCH PLAN submitted by SB in accordance with this Agreement or the JUNE 1996 SB/HGS LICENSE AGREEMENT
after the later of the end of the INITIAL RESEARCH TERM or RESEARCH TERM EXTENSIONS which HGS TECHNOLOGY at the time of such use is generally available to the public, and/or 

 

	 	23.3.2.	 use of SB TECHNOLOGY outside a RESEARCH PLAN submitted by SB in accordance with this Agreement or the JUNE 1996 SB/HGS LICENSE AGREEMENT developed
after the later of the end of the INITIAL RESEARCH TERM or RESEARCH TERM EXTENSIONS which is SB TECHNOLOGY only as a result of the use of unpatented HGS TECHNOLOGY which is generally available to the public at the time of such use; and/or

  

	 	23.3.3.	 use of BIOINFORMATICS after the end of the INITIAL RESEARCH TERM or RESEARCH TERM EXTENSION which BIOINFORMATICS is SB TECHNOLOGY; and/or

  

	 	23.3.4.	 use of SB TECHNOLOGY with respect to any products discovered four (4) years after the later of the end of the INITIAL RESEARCH TERM or RESEARCH
TERM EXTENSIONS outside a RESEARCH PLAN submitted by SB in accordance with this Agreement or the JUNE 1996 SB/HGS LICENSE AGREEMENT. 

  

	24.	 COUNTERPARTS 

  

	 	24.1.	 This Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed an original instrument, but all such
counterparts together shall constitute but one agreement. 

  
 29 

  
 IN
WITNESS WHEREOF, the parties, through their authorized officers, have executed this Agreement as of the date first written above. 
  

			
	 SmithKline Beecham Corporation

		
	 By:
	 	 [ILLEGIBLE]

	
	 SmithKline Beecham, p.l.c.

		
	 By:
	 	 [ILLEGIBLE]

	
	 Human Genome Sciences, Inc.

		
	 By:
	 	 [ILLEGIBLE]

		 	 President

  
 30 

  
 Appendix A 

SAMPLE DIAGNOSTIC RESEARCH PLAN 
  

	1.	 Background 

  

	 	a.	 Target Identification (HGS Sequence ID#) 

  

	 	b.	 Brief description of data regarding potential diagnostic utility 

 

	2.	 Key milestones 

  

	 	a.	 List key milestones and anticipated dates for achievement 

 

	 	b.	 Describe current status of project relative to milestones and associated dates for accomplishments 

 

	3.	 Clinical Evaluation 

  

	 	a.	 List clinical utility claims desired 

  

	 	b.	 Briefly describe the studies needed for clinical evaluation and status of those studies. 

 

	4.	 Patent Status 

  
 31

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00181-of-00352.parquet"}]]